Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16196958 | 0.88 | ALDH1A1 (0.41) | ROCK2CCR1CCR2RXFP1HSD17B3 | |
| SCHEMBL16197479 | 0.83 | RXFP1 (0.38) | ROCK2CCR1CCR2RXFP1PPARD | |
| SCHEMBL16196836 | 0.83 | CASP3 (0.39) | ROCK2CCR1CCR2HSD17B3PPARD | |
| SCHEMBL30203112 | 0.83 | PPARD (0.36) | ROCK2CCR1CCR2RXFP1HSD17B3 | |
| SCHEMBL16196957 | 0.82 | CCR1 (0.36) | ROCK2CCR1CCR2RXFP1PPARD | |
| SCHEMBL16196805 | 0.82 | CYP1A2 (0.40) | ROCK2CCR1CCR2RXFP1PPARD | |
| SCHEMBL16196974 | 0.81 | PPARD (0.39) | ROCK2CCR1CCR2RXFP1HSD17B3 | |
| SCHEMBL17558003 | 0.81 | AKR1B1 (0.39) | CCR1CCR2PPARDPPARAPPARG | |
| SCHEMBL16197188 | 0.80 | SMN1; SMN2 (0.39) | ROCK2CCR1CCR2RXFP1ALDH1A1 | |
| SCHEMBL16196806 | 0.80 | ALDH1A1 (0.40) | ROCK2CCR1CCR2RXFP1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663495-B2 | Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | YUHAN CORPORATION (KR) | 2017-05-30 | — | — | US | disclosed |
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2016-03-10 | — | — | US | disclosed |
| EP-2989093-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yuhan Corporation (KR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014175621-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GPR119, GPR88, GCGR | ROCK2 2378/4885CCR1 1694/4885CCR2 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.